Dutch Colorectal Cancer Group
Quick facts
Phase 3 pipeline
- capecitabine-irinotecan · Oncology
Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells. - epirubicin+cisplatin+capecitabine
- FOLFOX/ FOLFIRI with bevacizumab · Oncology
FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients. - FOLFOX/ FOLFIRI with panitumumab · Oncology
This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy. - FOLFOXIRI with bevacizumab · Oncology
FOLFOXIRI with bevacizumab combines three chemotherapy drugs (fluorouracil, oxaliplatin, and irinotecan) with an anti-angiogenic monoclonal antibody to kill colorectal cancer cells and block tumor blood vessel formation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Dutch Colorectal Cancer Group
What is Dutch Colorectal Cancer Group's pipeline?
Dutch Colorectal Cancer Group has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include capecitabine-irinotecan, epirubicin+cisplatin+capecitabine, FOLFOX/ FOLFIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab.
Related
- Sector hub: All tracked pharma companies